RETRACTED: QbD-based rivastigmine tartrate-loaded solid lipid nanoparticles for enhanced intranasal delivery to the brain for Alzheimer's therapeutics
Alzheimer's disease (AD) is a neurodegenerative disease that affects a wide range of populations and is the primary cause of death in various countries. The treatment of AD is still restricted to oral conventional medicines that act only superficially. Fabrication of intranasal solid lipid nano...
Main Authors: | Deepshi Arora, Shailendra Bhatt, Manish Kumar, Ravinder Verma, Yugam Taneja, Nikita Kaushal, Abhishek Tiwari, Varsha Tiwari, Athanasios Alexiou, Sarah Albogami, Saqer S. Alotaibi, Vineet Mittal, Rajeev K. Singla, Deepak Kaushik, Gaber El-Saber Batiha |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-08-01
|
Series: | Frontiers in Aging Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fnagi.2022.960246/full |
Similar Items
-
Double Optimization of Rivastigmine-Loaded Nanostructured Lipid Carriers (NLC) for Nose-to-Brain Delivery Using the Quality by Design (QbD) Approach: Formulation Variables and Instrumental Parameters
by: Sara Cunha, et al.
Published: (2020-06-01) -
Retraction: QbD-based rivastigmine tartrate-loaded solid lipid nanoparticles for enhanced intranasal delivery to the brain for Alzheimer's therapeutics
by: Frontiers Editorial Office
Published: (2024-03-01) -
Rivastigmine–Bambuterol Hybrids as Selective Butyrylcholinesterase Inhibitors
by: Jie Wu, et al.
Published: (2023-12-01) -
Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer's disease
by: Davide V Moretti, et al.
Published: (2014-07-01) -
Rivastigmine als ondersteuning bij het dilemma van de behandeling van hallucinaties optredend bij ziekte van Parkinson
by: jmp Rovers, et al.
Published: (2024-02-01)